



# CLX Investment Company, Inc.

(OTC BB: CLXN)

29970 Technology Drive, Suite 203, Murrieta, CA 92563

Telephone: (951) 677-6735 / Facsimile: (951) 677-6573

investors@clxinvestments.com

www.clxinvestments.com

## January 2008 Newsletter

### CLX Investment Company Prepares for Clinical Trials for Zonda's Rapid Point of Care Test for Chlamydia

#### Clinical Trials Scheduled for Mid to Late 1st Quarter 2008

**C**LX Investment Company (stock symbol - OTC BB: CLXN), which owns 51% of Zonda, Incorporated, a developer and manufacturer of unique diagnostic tests for the medical and non-medical markets, has announced that Safis Solutions, LLC is preparing to initiate clinical trials for Zonda's rapid point of care test for Chlamydia as part of the process to achieve FDA clearance for the product. CLX anticipates a mid to late first calendar quarter 2008 beginning for the clinical trials for the Zonda Chlamydia product.

Safis Solutions ([www.safis-solutions.com](http://www.safis-solutions.com)), an Indianapolis-based regulatory compliance consulting company serving pharmaceutical, medical device and biotech companies worldwide, has been retained as a sub-contractor of American Health Partners, LLC (AHP), which has been engaged by CLX to assist with the launch of medical diagnostic testing products in its subsidiary operations. Safis Solutions is providing ongoing consulting services in the areas of regulatory approvals and quality systems for Zonda and additional potential future medical diagnostic technologies acquired by CLX.

As part of the preparations for clinical trials, Safis has sent out bid requests to several Contract Research Organizations (CROs) to conduct the studies for Zonda, and CLX expects to have a contract in place with a CRO by the end of January.

Safis has initiated work on the testing protocol and will submit it to the FDA before testing begins. Safis has developed estimates on the number of expected clinical sites and the anticipated timeframe necessary to gather data. Once the clinical data is completed, the data will be analyzed and Safis Solutions will prepare and submit documents for FDA clearance, which will allow for its sale in the U.S.

"We are pleased with the schedule that Safis

(continued on page 2)

#### **CDC: Chlamydia Infections Top 1 Million Annually; Become Most Commonly Reported Notifiable Disease In The U.S.**

According to the "Centers for Disease Control and Prevention: 2006 Surveillance Data, Chlamydia," *Chlamydia trachomatis* infections are the most commonly reported notifiable disease in the United States. They are among the most prevalent of all STDs and, since 1994, have comprised the largest proportion of all STDs reported to CDC.

In women, chlamydial infections, which are usually asymptomatic, may result in pelvic inflammatory disease (PID), which is a major cause of infertility, ectopic pregnancy, and chronic pelvic pain. As with other inflammatory STDs, chlamydial infection can facilitate the transmission of HIV infection.

In addition, pregnant women infected with Chlamydia can pass the infection to their infants

(continued on page 2)

#### Inside This Issue

**CLX Files Annual Report and 8-K Related to Acquisition of Majority Zonda, Incorporated Subsidiary**

Page 2

**CEO Greeting - Vera Leonard Discusses 2008 Expectations**

Page 2

#### About the Company

CLX Investment Company, Inc. (OTC BB: CLXN) is a holding company seeking to provide long-term value for its shareholders by executing an acquisition strategy in the medical diagnostic testing field.

CLX owns a 51% equity interest in Zonda, Incorporated ([www.zondaincusa.com](http://www.zondaincusa.com)), a developer and manufacturer of unique diagnostic tests for both the medical and non-medical markets. The Company has announced a plan to acquire the remaining 49% of Zonda and plans to make this subsidiary a significant focus of CLX's operations.

CLX also holds a common stock position in ActionView International, Inc. ([www.actionviewinternational.com](http://www.actionviewinternational.com)), a publicly traded company that designs, develops, and manufactures vividly illuminated motion billboards.

## CLX Files Annual Report and 8-K on Zonda Acquisition

CLX has filed its annual report on Form 10-KSB for the 2007 fiscal year and the Current Report on Form 8-K/A related to its recent acquisition of a majority percentage of Zonda.

"Beyond meeting the company's reporting requirements, the filing of these two reports serves as an appropriate beginning of a new year for CLX," commented Vera Leonard, president and chief executive officer of the company. "Since CLX acquired a majority ownership percentage of Zonda several months ago, much has been accomplished, particularly in evaluating the status of Zonda and charting the most advantageous direction for this subsidiary. As our recent update detailed, we, along with American Health Partners and Safis Solutions, have developed and are executing a strategy to maximize Zonda's future potential. This strategy includes the anticipated start-up of clinical testing of Zonda's rapid point of care test for Chlamydia in the mid to late first calendar quarter of the year as part of the process to achieve FDA clearance for the product. We are also developing a new European distribution strategy for Zonda's Chlamydia product, and we expect to announce the details of this new strategy in the coming weeks.

"In addition to our work with Zonda, CLX will in continue to seek out and identify additional innovative products as potential acquisitions and opportunities for licensing and/or distribution relationships for CLX. 2008 is expected to be an eventful year for CLX, we are pleased to have these two reports filed, and we hope that our shareholders are as excited as we are about the possibilities," Ms. Leonard added.

## Clinical Trials for Zonda Chlamydia Product Scheduled

(continued from page 1)

Solutions has developed for clinical trials and subsequent work related to the planned FDA submission for Zonda's Chlamydia test," stated Vera Leonard, president and chief executive officer of CLX Investment Company. "The anticipated timetable for the FDA submission should compare very favorably with the standard expectations for the process. We look forward to initiating the clinical trials under the guidance of Safis Solutions and AHP, and we plan to keep CLX shareholders updated with any reportable milestones in the process."

## CDC Reports Increased Chlamydia Infections

(continued from page 1)

during delivery, potentially resulting in neonatal ophthalmia and pneumonia. Due to the large burden of disease and risks associated with infection, CDC recommends screening all sexually active women younger than 26 years of age for Chlamydia annually.

According to the estimates from the U.S. Census Department, in July 2006 there were 42,435,426 females between the ages of 15 years and 24 years of age. In 2006, 1,030,911 chlamydial infections were reported from 50 states and the District of Columbia. This is the first time in history that reported cases of Chlamydia in the U.S. have exceeded 1 million.

## Greetings from the CEO

CLX begins the 2008 calendar year looking forward to reaching a number of milestones, each of which has the potential to deliver significant value to the company. These include the scheduled initiation of clinical trials for Zonda's rapid point of care Chlamydia test, which is discussed extensively in this newsletter, and the potential acquisition, licensing and/or distribution of additional products and technologies by CLX.



As we look forward to these events that we expect to occur in 2008, I would like to take this opportunity to review what was achieved in the latter half of 2007.

CLX acquired a majority percentage of Zonda with the purchase of an additional 5% interest, bringing CLX's ownership percentage to 51%. Subsequently, CLX and Zonda implemented a plan under which CLX would purchase the remaining 49% of Zonda, assuming certain milestones are met.

Since CLX achieved majority control of Zonda with a 51% equity position, an 8-K filing was required within a 71 days and such a filing was recently completed within the specified timeframe. The 8-K contained Zonda's financials, which were included in CLX's consolidated financials.

I was pleased to accept the appointment to serve as CEO of CLX shortly after the majority ownership of Zonda was achieved. Several months earlier, when I was appointed as CEO of Zonda, I undertook an assessment of the company and its operations and began identifying the areas that needed immediate attention. These included the status of Zonda's FDA submission, its patent application, and its European sales and distribution program. The results of my assessment are included in this edition and we are pleased to report that since these aspects were first evaluated, there has been tangible progress in improving Zonda's position in each area.

We have also established some very important relationships recently, specifically those with American Health Partners (AHP) and Safis Solutions. These have already been fruitful associations, and we expect that 2008 will demonstrate truly how valuable these contractors can become for CLX and the technologies with which we become involved. As we evaluate some of the opportunities that have already been presented to us during our visit to the MEDICA trade fair last fall, we will look to become involved with additional quality medical diagnostic testing technologies that have potential for distribution in the United States.

I hope shareholders will continue to track our progress as we work to achieve our goals in 2008 and beyond.

Regards,

Vera Leonard  
Chief Executive Officer

### Forward-Looking Statements

All statements included in this release, including statements regarding potential future plans and objectives of CLX Investments are forward-looking statements. Such statements are necessarily subject to risks and uncertainties, some of which are significant in scope and nature beyond CLX Investments' control. There can be no assurance that such statements will prove accurate. Actual results and future events could differ materially from those anticipated in such statements depending on many factors. Historical results are not necessarily indicative of future performance.